MEI Pharma (MEIP) 10-K 9 Sep 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Sep. 05, 2014	Dec. 31, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'MEIP	'	'
Entity Registrant Name	'MEI Pharma, Inc.	'	'
Entity Central Index Key	'0001262104	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	21,607,296	'
Entity Public Float	'	'	$132,300,000

Balance_Sheets

Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$13,777	$35,573
Short-term investments	35,016	'
Prepaid expenses and other current assets	497	456
Total current assets	49,290	36,029
Intangible assets, net	435	470
Property and equipment, net	83	48
Total assets	49,808	36,547
Current liabilities:	'	'
Accounts payable	1,708	537
Accrued liabilities	2,908	1,138
Total current liabilities	4,616	1,675
Commitments and contingencies (Note 8)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value; 100,000 shares authorized; none outstanding	0	0
Common stock, $0.00000002 par value; 113,000,000 shares authorized; 21,607,296 and 17,116,571 shares issued and outstanding at June 30, 2014 and 2013, respectively	0	0
Additional paid-in-capital	168,637	131,169
Accumulated deficit	-123,445	-96,297
Total stockholders' equity	45,192	34,872
Total liabilities and stockholders' equity	$49,808	$36,547

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	113,000,000	113,000,000
Common stock, shares issued	21,607,296	17,116,571
Common stock, shares outstanding	21,607,296	17,116,571

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Operating expenses:	'	'	'
Research and development	($19,331)	($6,084)	($4,915)
General and administrative	-7,897	-5,138	-3,479
Total operating expenses	-27,228	-11,222	-8,394
Loss from operations	-27,228	-11,222	-8,394
Other income (expense):	'	'	'
Interest and dividend income	81	37	39
Adjustments to fair value of derivatives	'	'	1,139
Financing costs	'	'	-406
Gain on sale of investment	'	'	100
Income tax expense	-1	-1	-1
Net loss	($27,148)	($11,186)	($7,523)
Net loss per share, basic and diluted	($1.35)	($1.10)	($3.35)
Weighted average shares outstanding - basic and diluted	20,061,387	10,160,835	2,247,709

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (USD $)	Total	Series A Preferred Shares	Series B Preferred Shares	Common Shares	Additional paid in capital	Accumulated Deficit
In Thousands, except Share data	USD ($)				USD ($)	USD ($)
Beginning Balance at Jun. 30, 2011	$1,794	'	'	'	$79,382	($77,588)
Beginning Balance (in shares) at Jun. 30, 2011	'	1,000	0	1,480,181	'	'
Net loss	-7,523	'	'	'	'	-7,523
Issuance of common stock (in shares)	'	'	'	1,936,310	'	'
Issuance of common stock	9,831	'	'	'	9,831	'
Amendment of warrant terms	-14	'	'	'	-14	'
Share-based compensation expense	511	'	'	'	511	'
Ending Balance at Jun. 30, 2012	4,599	'	'	'	89,710	-85,111
Ending Balance (in shares) at Jun. 30, 2012	'	1,000	0	3,416,491	'	'
Net loss	-11,186	'	'	'	'	-11,186
Issuance of common stock (in shares)	'	'	'	12,699,824	'	'
Issuance of common stock	39,453	'	'	'	39,453	'
Conversion of Series A preferred stock	'	-1,000	'	804,500	'	'
Issuance of common stock for purchase of intangible assets (in shares)	'	'	'	195,756	'	'
Issuance of common stock for purchase of intangible assets	500	'	'	'	500	'
Share-based compensation expense	1,506	'	'	'	1,506	'
Ending Balance at Jun. 30, 2013	34,872	'	'	'	131,169	-96,297
Ending Balance (in shares) at Jun. 30, 2013	'	0	0	17,116,571	'	'
Net loss	-27,148	'	'	'	'	-27,148
Issuance of common stock (in shares)	'	'	'	4,375,000	'	'
Issuance of common stock	32,695	'	'	'	32,695	'
Exercise of warrants	26	'	'	'	26	'
Exercise of warrants(in shares)	'	'	'	115,725	'	'
Share-based compensation expense	4,747	'	'	'	4,747	'
Ending Balance at Jun. 30, 2014	$45,192	'	'	'	$168,637	($123,445)
Ending Balance (in shares) at Jun. 30, 2014	'	0	0	21,607,296	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:	'	'	'
Net loss	($27,148)	($11,186)	($7,523)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Share-based compensation	4,747	1,506	511
Gain on adjustment to fair value of derivatives	'	'	-1,139
Financing costs	'	'	406
Depreciation and amortization	50	45	13
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses and other current assets	-41	-310	126
Accounts payable	1,171	-57	266
Accrued liabilities	1,770	-42	259
Net cash used in operating activities	-19,451	-10,044	-7,081
Cash flows from investing activities:	'	'	'
Purchases of property and equipment	-50	-38	'
Acquisition of short-term investments, net	-35,016	'	'
Net cash used in investing activities	-35,066	-38	'
Cash flows from financing activities:	'	'	'
Net proceeds from issuance of common stock	32,721	39,453	9,831
Financing costs	'	'	-406
Net cash provided by financing activities	32,721	39,453	9,425
Net (decrease) increase in cash and cash equivalents	-21,796	29,371	2,344
Cash and cash equivalents at beginning of the period	35,573	6,202	3,858
Cash and cash equivalents at end of the period	13,777	35,573	6,202
Supplemental cash flow information:	'	'	'
Income taxes paid	($1)	($1)	($1)
Issuance of common stock for purchase of intangible assets	'	500	'

The_Company_and_Summary_of_Sig

The Company and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
The Company and Summary of Significant Accounting Policies	'
	Note 1. The Company and Summary of Significant Accounting Policies
	The Company
	MEI Pharma, Inc. (formerly Marshall Edwards, Inc.), or the Company, is an oncology company focused on the clinical development of novel therapeutics for cancer. The Company’s common stock is listed on the Nasdaq Capital Market under the symbol “MEIP”. The Company was incorporated in December 2000 as a wholly-owned subsidiary of Novogen Limited (“Novogen”). In December 2012, Novogen distributed to its shareholders substantially all of its MEI Pharma common stock.
	The Company’s business purpose is the development of drugs for the treatment of cancer. The Company is principally focused on the clinical development of its lead drug candidate, Pracinostat, which it is currently investigating in three Phase II clinical trials. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor that is being developed for advanced hematologic diseases such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In August 2012, the Company acquired certain assets and intellectual property, including those related to Pracinostat, from S*Bio Pte Ltd (“S*Bio”). The Company’s clinical development pipeline also includes its isoflavone-based mitochondrial inhibitor drug candidate, ME-344. Results from a Phase I clinical trial of ME-344 in patients with refractory solid tumors were presented in October 2013. The Company initiated a Phase Ib trial in patients with small cell lung cancer and ovarian cancer in May 2014. In September 2013, the Company acquired PWT143, an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that has been shown to play a critical role in the proliferation and survival of hematologic cancer cells. The Company expects to complete the pre-clinical work required to support the filing of an Investigational New Drug (IND) application for PWT143 by the end of calendar year 2014.
	The results of pre-clinical studies and completed clinical trials are not necessarily predictive of future results, and the Company’s current drug candidates may not have favorable results in later studies or trials. The commercial opportunity will be reduced or eliminated if competitors develop and market products that are more effective, have fewer side effects or are less expensive than the Company’s drug candidates. The Company will need substantial additional funds to progress the clinical trial program for the drug candidates Pracinostat, ME-344 and PWT143, and to develop new compounds. The actual amount of funds that will be needed are determined by a number of factors, some of which are beyond the Company’s control. Negative U.S. and global economic conditions may pose challenges to the Company’s business strategy, which relies on funding from the financial markets or collaborators.
	Reverse Stock Split and Presentation
	On December 18, 2012, the Company effected a 1-for-6 reverse stock split (the “2012 Reverse Stock Split”) of the Company’s common stock. As a result of the 2012 Reverse Stock Split, every six shares of the Company’s issued and outstanding common stock were combined into one share of common stock. The 2012 Reverse Stock Split did not change the number of authorized shares of the Company’s common stock, nor the common stock par value. All financial data and share information is presented on an as-adjusted basis to give effect to the 2012 Reverse Stock Split.
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities.” ASU 2014-10 removes the financial reporting distinction between development stage entities and other reporting entities in United States Generally Accepted Accounting Principles. The amendment therefore eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. We early adopted ASU 2014-10 retrospectively during the year ended June 30, 2014; while the adoption of this standard impacted financial statement presentation and disclosure, it did not have a material impact on our financial condition, results of operations or cash flows.
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under accounting principles generally accepted in the Unites States of America (“U.S. GAAP”). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). Currently the Company is not generating any revenue. Therefore, the Company has not yet determined the transition method by which they will adopt the standard in 2017.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. The Company uses estimates for certain accruals including clinical and pre-clinical study fees and expenses, share-based compensation, and valuations of derivative liabilities, among others. Actual results could materially differ from those estimates.
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased.
	Short-Term Investments
	Investments that have maturities of greater than three months but less than one year at the time of purchase are classified as short-term investments. Short-term investments are comprised of money market funds and U.S. government securities and are recorded at their amortized cost.
	Fair Value of Financial Instruments
	The carrying amounts of financial instruments such as cash equivalents and other current liabilities approximate the related fair values due to the short-term maturities of these instruments. The Company invests its excess cash in financial instruments which are readily convertible into cash, consisting of money market funds and U.S. government securities. Cash is deposited in financial institutions that are FDIC insured; these deposits are in excess of the FDIC insurance limits. Financial instruments include cash and cash equivalents, short-term investments and accounts payable, which approximate fair value because of their short maturities.
	The fair value of financial assets and liabilities is measured under a three-tier fair value hierarchy as follows: Level 1 fair value is determined from observable, quoted prices in active markets for identical assets or liabilities. Level 2 fair value is determined from quoted prices for similar items in active markets or quoted prices for identical or similar items in markets that are not active. Level 3 fair value is determined using the entity’s own assumptions about the inputs that market participants would use in pricing an asset or liability. Cash equivalents, where applicable, and short-term investments are classified as Level 1 as defined by the fair value hierarchy.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash in financial institutions (which exceeds federally insured limits), and cash equivalents and short-term investments (comprised of U.S. government securities). However, management believes that the Company is not exposed to significant credit risk due to the financial positions of the depository institutions in which these deposits are held.
	Intangible Assets
	Intangible assets consist of patents acquired from S*Bio in August 2012, relating to a family of heterocyclic compounds that inhibit HDACs. Capitalized amounts are amortized on a straight-line basis over the expected life of the intellectual property of 14 years. The carrying values of intangible assets are periodically reviewed to determine if the facts and circumstances suggest that a potential impairment may have occurred. Results of operations for the years ended June 30, 2014 and 2013 do not reflect any write-downs associated with the potential impairment of intangible assets.
	Property and Equipment
	Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (generally three to seven years) using the straight-line method. Leasehold improvements are stated at cost and are amortized over the shorter of the estimated useful lives of the assets or the lease term.
	Research and Development Costs
	Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. The Company accrues research and development costs based on work performed. In determining the amount to accrue, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.
	License Fees
	Costs incurred related to the licensing of products that have not yet received regulatory approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.
	Share-based Compensation
	Share-based compensation expense for employees and directors is recognized in the statement of operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, the Company estimates the grant date fair value using a binomial valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. The Company estimates the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from our estimated volatility at the grant date. For restricted stock unit (RSU) equity awards, the Company estimates the grant date fair value using the Company’s closing stock price on the date of grant. Share-based compensation recorded in the statement of operations is based on the awards expected to ultimately vest and has been reduced for estimated forfeitures. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. The Company recognizes the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which the share-based awards vest.
	Interest and Dividend Income
	Interest on cash balances is recognized when earned. Dividend income is recognized when the right to receive the payment is established.
	Income Taxes
	The Company’s income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of June 30, 2014 and 2013, the Company has established a valuation allowance to fully reserve its net deferred tax assets. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership of the Company may limit the amount of net operating loss carry-forwards that can be utilized in the future to offset taxable income.
	The FASB Topic on Income Taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There were no unrecognized tax benefits as of June 30, 2014 and 2013.
	Derivative Liabilities
	The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded at fair value as additional paid-in capital on our balance sheet and are not marked to market. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised, amended to remove features that result in derivative liability classification, or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of the Company’s derivative liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate. All instruments creating derivative liability accounting treatment were settled during the year ended June 30, 2012. There were no derivative liabilities as of June 30, 2014 or June 30, 2013.
	Net Loss Per Share
	Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the years ended June 30, 2014, 2013 and 2012.
	Net loss per share was determined as follows (in thousands, except share and per share amounts):
		Years ended June 30,
		2014			2013			2012
	Numerator
	Net loss	$	(27,148	)	$	(11,186	)	$	(7,523	)
	Denominator
	Weighted average common shares outstanding		20,061,387			10,160,835			2,247,709
	Basic and diluted net loss per share	$	(1.35	)	$	(1.10	)	$	(3.35	)
	Because the Company is in a net loss position, it has excluded stock options, warrants, unvested restricted stock units and convertible preferred stock from its calculation of diluted net loss per share, and the Company’s diluted net loss per share is the same as the Company’s basic net loss per share. For the years ended June 30, 2014, 2013 and 2012, the Company did not have any items that would be classified as other comprehensive income or losses. The table below presents the potentially dilutive securities that would have been included in the Company’s calculation of diluted net loss per share allocable to common stockholders as if they were not antidilutive as of June 30, 2014, 2013 and 2012.
		Year ended June 30,
		2014			2013			2012
	Anti-dilutive securities not included in diluted loss per share:
	Stock options		1,194,854			635,094			143,927
	Warrants		4,900,999			5,062,000			937,295
	Restricted stock units		400,000			400,000			—
	Convertible preferred shares		—			—			804,500
	Total anti-dilutive securities not included in diluted net loss per share		6,495,853			6,097,094			1,885,722

Intangible_Assets

Intangible Assets	12 Months Ended
	Jun. 30, 2014
Intangible Assets	'
	Note 2. Intangible Assets
	Intangible assets consisted of the following, in thousands:
		June 30,
		2014			2013
	S*Bio Patents – Gross	$	500		$	500
	S*Bio Patents – Accumulated amortization		(65	)		(30	)
	Intangible assets, net	$	435		$	470
	Amortization expense of intangible assets for the years ended June 30, 2014 and 2013 was $35,000 and $30,000, respectively, with no amortization expense during the year ended June 30, 2012. We expect to record amortization of $35,000 per year through 2026 for our S*Bio patents.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2014
Property and Equipment	'
	Note 3. Property and Equipment
	Property and equipment consisted of the following, in thousands:
		June 30,
		2014			2013
	Furniture and equipment	$	107		$	67
	Leasehold improvements		32			22
			139			89
	Less: accumulated depreciation		(56	)		(41	)
	Property and equipment, net	$	83		$	48
	Depreciation expense of property and equipment for the years ended June 30, 2014, 2013 and 2012 was $15,000, $15,000 and $13,000, respectively.

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Jun. 30, 2014
Accrued Liabilities	'
	Note 4. Accrued Liabilities
	Accrued liabilities consisted of the following, in thousands:
		June 30,
		2014		2013
	Accrued pre-clinical and clinical trial expenses	$	1,899	$	279
	Accrued compensation and benefits		800		604
	Accrued legal and professional services expenses		102		145
	Other		107		110
	Total accrued liabilities	$	2,908	$	1,138

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2014
Related Party Transactions	'
	Note 5. Related Party Transactions
	Novogen was the Company’s majority shareholder from the Company’s inception through December 3, 2012. On such date, Novogen completed the distribution of substantially all of its MEI Pharma common stock to its shareholders. Historically, the Company licensed from Novogen the rights to Novogen patents and applications for the Company’s isoflavone-based drug candidates, as well as other compounds. Additionally, Novogen historically provided research and development services and administrative and finance services to the Company under service agreements. The Company’s license agreements with Novogen were terminated in May 2011 in conjunction with the Isoflavone Transaction. The service agreements with Novogen were terminated in December 2010.
	Rights Offering
	In March 2012, the Company distributed one subscription right for each share of common stock and each Series A warrant exercisable for a share of common stock to holders of record as of March 30, 2012. Each subscription right entitled the holder to purchase one Unit, which consisted of 0.0833 shares of our common stock and a warrant representing the right to purchase 0.04167 shares of the Company’s common stock. In connection with the rights offering, in May 2012, Novogen purchased 8,988,675 units consisting of 749,056 shares of common stock and warrants to purchase an additional 374,528 shares of common stock. The warrants are exercisable for a five-year period beginning on May 11, 2012 at an exercise price of $7.14 per share. See further discussion regarding the Rights Offering in Note 6 “Stockholders’ Equity”.
	Waiver Agreement
	In December 2012, the Company entered into an agreement (the “Waiver Agreement”) with Novogen and Novogen Research Pty Limited, a wholly-owned subsidiary of Novogen (together, the “Novogen Parties”), Graham Kelly, an individual, and Andrew Heaton, an individual, pursuant to which the Company granted a limited waiver with respect to certain non-compete provisions contained in the Asset Purchase Agreement dated as of December 20, 2010, between the Company and the Novogen Parties. In consideration of the Company’s grant of the limited waiver, upon the execution of the Waiver Agreement, Novogen surrendered to the Company for cancellation warrants held by Novogen for the purchase of 166,666 shares of Common Stock.
	Securities Subscription Agreements
	In September 2011, the Company entered into a Securities Subscription Agreement with Novogen, pursuant to which the Company sold to Novogen 222,222 shares of common stock, at a purchase price of $9.00 per share, for proceeds of $2.0 million. The offering closed on September 29, 2011. In December 2011, the Company entered into a Securities Subscription Agreement with Novogen, pursuant to which the Company sold to Novogen 323,625 shares of common stock, at a purchase price of $6.18 per share, for proceeds of $2.0 million. The offering closed on December 29, 2011.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity	'
	Note 6. Stockholders’ Equity
	Equity Transactions
	Underwritten Registered Offerings
	In October 2013, the Company completed an underwritten registered offering of 4,375,000 shares of its common stock at a price per share of $8.00 pursuant to a “shelf” registration statement previously filed and declared effective by the Securities and Exchange Commission. The Company received net proceeds of $32.7 million associated with the offering.
	In April 2013, the Company completed an underwritten registered offering of 2,030,000 shares of its common stock at a price per share of $7.50 pursuant to a “shelf” registration statement previously filed and declared effective by the Securities and Exchange Commission. The Company received net proceeds of $14.2 million associated with the offering.
	Private Placement
	In December 2012, the Company completed the sale (the “December 2012 private placement”) of 9,166,665 shares of common stock and warrants to purchase an additional 6,416,665 shares of common stock for an aggregate offering price of $27.5 million, pursuant to the terms of the Securities Purchase Agreement, dated November 4, 2012, between the Company and certain accredited investors identified therein. The Company received net proceeds of $25.3 million associated with the Private Placement. In the period from December 2012 through June 2014, the investors exercised, on a cashless basis, warrants representing the right to purchase 2,046,871 shares of common stock. The Company issued 1,496,018 shares of common stock in conjunction with the exercise of the warrants.
	S*Bio Asset Purchase
	In August 2012, the Company acquired from S*Bio certain assets comprised of intellectual property and technology including rights to Pracinostat, in exchange for 195,756 shares of common stock valued at $0.5 million (see Note 8).
	Rights Offering
	In May 2012, the Company completed a rights offering (“Rights Offering”) pursuant to which the Company distributed, at no charge, to holders of record as of March 30, 2012, subscription rights (the “Rights”) to purchase up to 17,129,361 units for an aggregate purchase price of up to $7.6 million. The subscription period for the Rights Offering expired on May 11, 2012. Each unit consisted of 0.0833 shares of common stock and a warrant representing the right to purchase 0.04167 shares of common stock at an exercise price of $7.14 per share. The exercise of one Right entitled holders to purchase one unit at a subscription price of $0.445 per unit, which represented the subscription price of $5.34 per whole share. Eligible participants in the Rights Offering exercised Rights to purchase an aggregate of 11,660,606 units; accordingly, the Company issued 971,700 shares of common stock and warrants to purchase an additional 485,857 shares of common stock. The warrants are exercisable for a five-year period beginning on May 11, 2012. The Company received net proceeds of $4.8 million associated with the Rights Offering. In December 2012, upon the execution of the Waiver Agreement, Novogen surrendered to the Company for cancellation warrants acquired by Novogen in the Rights Offering for the purchase of 166,666 shares of common stock. In the period from March 2013 through June 2014, holders exercised warrants acquired in the Rights Offering representing the right to purchase 3,707 shares of common stock.
	Private Placements with Novogen
	In September 2011, the Company entered into a Securities Subscription Agreement with Novogen, pursuant to which the Company sold to Novogen 222,222 shares of the Company’s common stock, at a purchase price of $9.00 per share, for proceeds of $2.0 million. The offering closed on September 29, 2011. In December 2011, the Company entered into a Securities Subscription Agreement with Novogen, pursuant to which the Company sold to Novogen 323,625 shares of our common stock, at a purchase price of $6.18 per share, for proceeds of $2.0 million. The offering closed on December 29, 2011.
	May 2011 Private Placement
	In May 2011, the Company entered into an Amended and Restated Securities Purchase Agreement (the “Amended Securities Purchase Agreement”) with certain accredited investors pursuant to which the Company agreed to issue and sell to the investors certain shares of the Company’s common stock, and warrants to purchase additional shares of common stock. Pursuant to the Amended Securities Purchase Agreement, in May 2011 the Company issued to the investors: (i) 139,203 shares (the “Initial Shares”) of common stock, at a purchase price of $8.00 per share; (ii) series A warrants (the “Series A warrants”) which initially represented the right to purchase up to 104,402 shares of common stock, up to a maximum of 375,094 shares; and (iii) series B warrants (the “Series B warrants”) which initially represented the right to purchase up to 360,922 shares of common stock. In addition, the Company agreed to issue certain additional shares of common stock (the “Adjustment Shares”) to the extent the price of the common stock is below $8.00 per share, but greater than or equal to $4.50 per share, on certain dates (“Adjustment Dates”) during the period ending June 26, 2012, including as a result of a subsequent offering by the Company of its securities at a price below the purchase price of the Initial Shares. The number of Adjustment Shares issuable was initially limited to 108,207, subject to proportionate increases to the extent the Series B warrants have been exercised prior to the applicable Adjustment Date, up to a maximum of 388,764 shares. If the trading price of the Company’s common stock is below $4.50 per share on any Adjustment Date, the Company will, in addition to issuing the applicable number of Adjustment Shares, refund to the investors an amount per share of common stock received by the investors in the transaction equal to the difference between $4.50 and the price of the common stock on such Adjustment Date. The transactions contemplated by the Amended Securities Purchase Agreement are referred to as the May 2011 private placement. Upon the closing of the May 2011 private placement, the Company also issued warrants to the placement agent for the purchase of up to 35,008 shares of common stock, which warrants were exercisable on the same terms as the Series A warrants.
	On December 29, 2011, the Company issued an aggregate of 111,212 Adjustment Shares to the investors in accordance with the calculation of the applicable price, based on the trading price of the Company’s common stock, with respect to the first Adjustment Date. Additionally, on December 29, 2011, the Company issued an aggregate of 40,950 Adjustment Shares to the investors in connection with the private placement of common stock to Novogen that closed on December 29, 2011.
	Terms of Series A and Series B Warrants
	The Series A warrants became exercisable on the six month anniversary of the May 18, 2011 closing of the May 2011 private placement. The Series A warrants will expire on the fifth anniversary of the date on which the Series A warrants first became exercisable. Prior to the amendment of the warrant terms in September 2011 in conjunction with the Supplemental Agreement, as defined and described below, the Series A warrants were initially exercisable at an exercise price of $9.42 per share, subject to adjustment as provided in the Series A warrant agreements. Under the terms of the warrant agreements, the number of shares of common stock issuable upon exercise of the Series A warrants would be increased by an amount equal to 75% of the number of shares of common stock issued upon each exercise of the Series B warrants.
	Prior to the amendment of the warrant terms in September 2011 in conjunction with the Supplemental Agreement, as described below, the initial exercise price per share of the Series B warrants was equal to the lower of (i) $8.00, and (ii) 85% of the arithmetic average of the lowest eight weighted average prices of the common stock during the 20 consecutive trading day period in the case of a voluntary exercise by the holders, ending on the trading day immediately preceding the date of delivery of a notice of exercise.
	In July and August 2011, the investors exercised an aggregate of Series B warrants representing the right to purchase 215,667 shares of common stock. The Company received net proceeds of $1.1 million in conjunction with the exercise of the Series B warrants. Pursuant to the terms of the Amended Securities Purchase Agreement, an additional 161,750 Series A warrants became exercisable as a result of these Series B warrant exercises.
	Supplemental Agreement
	In September 2011, the Company entered into a Supplemental Agreement (the “Supplemental Agreement”) with each of the investors party to the Amended Securities Purchase Agreement.
	Pursuant to the Supplemental Agreement, each of the Series A warrants and the Series B warrants issued pursuant to the Amended Securities Purchase Agreement were amended and restated (the “Amended Series A Warrants” and “Amended Series B Warrants”, respectively). The exercise price of each of the Series A warrants and Series B warrants was reduced to $6.00 per share. As amended, the exercise price of the Amended Series A Warrants is no longer subject to further adjustment upon the occurrence of certain events, including the subsequent sale or deemed sale by the Company of shares of common stock at a price per share below the exercise price of the Amended Series A Warrants; however, the Amended Series A Warrants continue to provide for certain customary anti-dilution adjustments.
	The Series B warrants were amended to permit the exercise of such warrants on a cashless basis. Pursuant to the terms of the Supplemental Agreement, the investors exercised, on a cashless basis, the Amended Series B Warrants for all of the remaining shares of common stock for which such Amended Series B Warrants were exercisable, resulting in the exercise of Series B Warrants representing the right to purchase 145,256 shares of common stock and the issuance by the Company of an aggregate of 50,934 shares of common stock. Pursuant to the terms of the Amended Securities Purchase Agreement, additional Series A warrants to purchase 108,942 shares of common stock became exercisable as a result of these Series B warrant exercises. As of September 28, 2011, there were no remaining outstanding Series B warrants.
	In December 2012, the investors exercised, on a cashless basis, Series A warrants representing the right to purchase an aggregate of 194,381 shares of common stock. The Company issued 119,158 shares of common stock in conjunction with the exercise of the Series A warrants.
	The Supplemental Agreement also effected certain amendments to the Amended Securities Purchase Agreement, including the extension, through September 28, 2013, of the period during which the investors had the right to participate in subsequent equity offerings of the Company. In connection with the amendments described above, the Company made cash payments to the investors in an aggregate amount of $365,000, which, together with $41,000 that the Company paid in other expenses related to the Supplemental Agreement, have been classified as ‘Financing Costs’ in the Statement of Operations.
	Derivative Liabilities
	The Company accounted for the Series A and B warrants and the Adjustment Shares feature pursuant to the Amended Securities Purchase Agreement in accordance with accounting guidance for derivatives. As a result of the Company’s completion of its contractual obligations under the Amended Securities Purchase Agreement related to the issuance of Adjustment Shares during December 2011, the Company had no remaining derivative liabilities as of June 30, 2014 or June 30, 2013.
	On the closing date of the May 2011 private placement, the derivative liabilities were initially recorded at their estimated fair values of $1.2 million. The fair value of the derivative liabilities exceeded the proceeds of the private placement of $0.7 million, and accordingly, no net amounts were allocated to the common stock. The $508,000 amount by which the recorded liabilities exceeded the proceeds was charged to other expense. On June 30, 2011, the total value of the derivative liabilities was $1.1 million, resulting in other income of $49,000 classified as ‘Adjustments to Fair Value of Derivatives’ in the Statement of Operations. Such decrease in the estimated fair value was primarily due to the decrease in the Company’s common stock price and updates to the assumptions used in the option pricing models. The completion of the Company’s obligations related to the derivative liabilities during the year ended June 30, 2012 resulted in extinguishment of the derivative liabilities; accordingly, the Company recorded other income of $1.1 million, classified as ‘Adjustments to Fair Value of Derivatives’ in the Statement of Operations, associated with the decrease in fair value of the derivative liabilities. Additionally, during the year ended June 30, 2012, the Company recorded a gain of $14,000 in conjunction with amending the Series A warrant terms, based on the fair value of the Amended Series A Warrants, classified as ‘Adjustments to Fair Value of Derivatives’ in the Statement of Operations.
	Shelf Registration Statement
	In April 2014, the Company filed a shelf registration statement on Form S-3 with the SEC (the “new shelf registration statement”). The new shelf registration statement was declared effective by the SEC in April 2014. The new shelf registration statement permits the Company to sell, from time to time, up to $150 million of common stock, preferred stock and warrants. Pursuant to SEC regulations, if the market value of the Company’s public float is below $75 million, the Company cannot sell securities from the shelf registration statement which represent more than one third of the market value of the Company’s non-affiliated public float during any 12-month period.
	In April 2011, the Company filed a shelf registration statement on Form S-3 with the SEC (the “shelf registration statement”). The shelf registration statement was declared effective by the SEC in May 2011 and expired in April 2014. The shelf registration statement permits the Company to sell, from time to time, up to $50 million of common stock, preferred stock and warrants. In April 2013, the Company completed an underwritten registered offering of 2,030,000 shares of its common stock at a price per share of $7.50 pursuant to the shelf registration statement. In October 2013, the Company completed an underwritten registered offering of 4,375,000 shares of its common stock at a price per share of $8.00 pursuant to the shelf registration statement.
	Description of Capital Stock
	The Company’s total authorized share capital is 113,100,000 shares consisting of 113,000,000 shares of common stock, $0.00000002 par value per share, and 100,000 shares of preferred stock, $0.01 par value per share.
	Common Stock
	The holders of common stock are entitled to one vote per share. In the event of a liquidation, dissolution or winding up of the Company’s affairs, holders of the common stock will be entitled to share rateably in all the Company’s assets that are remaining after payment of the Company’s liabilities and the liquidation preference of any outstanding shares of preferred stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of common stock are subject to any series of preferred stock that the Company has issued or that the Company may issue in the future. The holders of common stock have no pre-emptive rights and are not subject to future calls or assessments by the Company.
	Preferred Stock
	The Company’s Board of Directors has the authority to issue up to 100,000 shares of preferred stock with par value of $.01 per share in one or more series and to fix the rights, preferences, privileges and restrictions in respect of that preferred stock, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption (including sinking fund provisions), redemption prices and liquidation preferences, and the number of shares constituting such series and the designation of any such series, without future vote or action by the stockholders. Therefore, the board without the approval of the stockholders could authorize the issue of preferred stock with voting, conversion and other rights that could affect the voting power, dividend and other rights of the holders of shares or that could have the effect of delaying, deferring or preventing a change of control. There were no shares of preferred stock outstanding as of June 30, 2014 or 2013.
	Warrants
	As of June 30, 2014, there were outstanding warrants to purchase 315,484 shares of the Company’s common stock at an exercise price of $7.14 per share, which expire in May 2017, issued in conjunction with the Rights Offering; outstanding Series A warrants and warrants issued to the Company’s placement agent for the May 2011 private placement to purchase up to 215,721 shares of common stock at an exercise price of $6.00 per share, which expire in November 2016, and warrants to purchase 4,369,794 shares of the Company’s common stock at an exercise price of $3.12 per share, which expire in December 2017, issued in conjunction with the December 2012 private placement.

Sharebased_Compensation

Share-based Compensation	12 Months Ended
	Jun. 30, 2014
Share-based Compensation	'
	Note 7. Share-based Compensation
	The Company uses equity-based compensation programs to provide long-term performance incentives for its employees. These incentives consist primarily of stock options and restricted stock units (RSUs). In December 2008, the Company adopted the MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation Plan (the “2008 Plan”), as amended and restated in 2011 and 2013, under which 2,186,000 shares of common stock are authorized for issuance. The 2008 Plan provides for the grant of options and/or other stock-based or stock-denominated awards to the Company’s non-employee directors, officers, employees and advisors. As of June 30, 2014, there were 657,479 shares available for future grant under the 2008 Plan.
	Total share-based compensation expense for all stock awards consists of the following, in thousands:
		Years Ended June 30,
		2014			2013			2012
	Research and development	$	1,549		$	213		$	65
	General and administrative		3,198			1,293			446
	Total share-based compensation	$	4,747		$	1,506		$	511
	Stock Options
	As of June 30, 2014, there were a total of 1,194,854 options outstanding, including options representing the right to purchase a total of 66,333 shares of common stock which were granted to two of the Company’s officers outside of the 2008 Plan.
	A summary of the Company’s stock option activity and related data follows:
		Number of			Weighted-Average			Weighted-Average			Aggregate
		Options			Exercise Price			Remaining Contractual			Intrinsic Value
								Term (in years)
	Outstanding at June 30, 2013		635,094		$	8.26
	Granted		568,593			7.97
	Expired		(8,833	)		10.33
	Outstanding at June 30, 2014		1,194,854		$	8.11			3.7		$	340,397
	Vested and exercisable at June 30, 2014		326,363		$	8.94			2.7		$	173,574
	No stock option exercises occurred during the years ended June 30, 2014, 2013 or 2012. As of June 30, 2014, the aggregate intrinsic value of outstanding options is calculated as the difference between the exercise price of the underlying options and the closing price of the Company’s common stock of $6.34 on that date. The total fair value of options that vested during the years ended June 30, 2014, 2013, and 2012 was $1.2 million, $0.9 million, and $0.3 million, respectively.
	Unrecognized compensation expense related to non-vested stock options totalled $3.3 million as of June 30, 2014. Such compensation expense is expected to be recognized over a weighted-average period of 3.1 years. As of June 30, 2014, the Company expects all outstanding options to vest.
	The Company uses a binomial valuation model to estimate the grant date fair value of stock options. To calculate these fair values, the following weighted-average assumptions were used:
		Years ended June 30,
		2014			2013			2012
	Risk-free interest rate		1.5	%		0.7	%		1.2	%
	Expected life (years)		5			5			5
	Expected volatility		145.9	%		159.3	%		146.5	%
	Dividend yield		0	%		0	%		0	%
	Grant date fair value	$	6.85		$	6.57		$	8.56
	Restricted Stock Units
	On March 29, 2013, the Compensation Committee of the Board of Directors granted 400,000 RSUs to the Company’s Chief Executive Officer, Dr. Daniel P. Gold. Each RSU represents the contingent right to receive one share of the Company’s common stock. One third of the RSUs will vest on each of August 30, 2014, August 30, 2015 and August 30, 2016. The shares underlying the RSUs will be delivered to Dr. Gold on the earliest to occur of (i) March 29, 2018, (ii) Dr. Gold’s death, disability or separation from service from the Company for any reason, or (iii) a change in control involving the Company.
	The fair value of the RSUs on the date of grant was $3.5 million. The grant date fair value per unit was $8.63. As of June 30, 2014, unrecognized compensation expense related to the unvested portion of the Company’s RSUs was approximately $1.4 million and is expected to be recognized over approximately 2.2 years.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
	Note 8. Commitments and Contingencies
	The Company has contracted with various consultants and third parties to assist it in pre-clinical research and development and clinical trials work for its leading drug compounds. The contracts are terminable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. The Company also has employment agreements with certain of its current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances.
	The Company currently leases approximately 8,800 square feet of office space for the Company’s executive and administrative offices. The monthly rental rate ranges from $25,077 to $25,957 during the remaining term of the lease, plus a pro-rata share of certain building expenses. The lease expires in June 2015. Future minimum payments under the lease are $303,000 as of June 30, 2014.
	Asset Purchase Agreement
	On August 7, 2012, the Company entered into a definitive asset purchase agreement with S*Bio, pursuant to which the Company agreed to acquire certain assets comprised of intellectual property and technology including rights to Pracinostat, in exchange for $500,000 of common stock. On August 22, 2012, the Company completed the asset purchase and issued 195,756 shares of common stock to S*Bio. The Company has also agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $75.2 million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U. and Japan. The first milestone payment of $200,000 plus shares of the Company’s common stock having a value of $500,000 will be due upon the first dosing of a patient in a Phase III clinical trial or other pivotal trial, for any indication. Subsequent milestone payments will be due upon certain regulatory approvals. S*Bio will be entitled to receive certain contingent earnout payments based on certain worldwide net sales thresholds on a product-by-product and country-by-country basis. As of June 30, 2014, the Company has not accrued any amounts for potential future payments.
	License Agreement
	On September 28, 2012, the Company entered into a license agreement with CyDex Pharmaceuticals, Inc. (“CyDex”). Under the license agreement, CyDex granted to the Company an exclusive, nontransferable license to intellectual property rights relating to Captisol® for use with the Company’s two isoflavone-based drug compounds. The Company agreed to pay to CyDex a non-refundable license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales of the Company’s approved drugs utilizing Captisol. Contemporaneously with the license agreement, the Company and CyDex entered into a commercial supply agreement pursuant to which the Company agreed to purchase 100% of its requirements for Captisol from CyDex. The Company may terminate both the license agreement and the supply agreement for convenience at any time upon 90 days’ prior written notice. As of June 30, 2014, the Company has not accrued any amounts for potential future payments.

Segment_Information

Segment Information	12 Months Ended
	Jun. 30, 2014
Segment Information	'
	Note 9. Segment Information
	The Company has one operating segment, the development of pharmaceutical compounds. The Company’s business contained two geographic segments, the United States of America and Australia, from inception until MEPL’s legal dissolution in April 2012. For the year ended June 30, 2012, net losses attributable to Australia were immaterial. All of the Company’s assets and liabilities were located in the United States of America as of June 30, 2014 and June 30, 2013.

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Taxes	'
	Note 10. Income Taxes
	Pre-tax loss consists of the following jurisdictions (in thousands):
		Years ended June 30,
		2014			2013			2012
	Domestic	$	(27,147	)	$	(11,185	)	$	(8,546	)
	Foreign		—			—			1,024
	Pre-tax loss	$	(27,147	)	$	(11,185	)	$	(7,522	)
	The reconciliation of income tax computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):
		Years Ended June 30,
		2014						2013						2012
		$			%			$			%			$			%
	Tax benefit at U.S. statutory rates	$	9,230			34	%	$	3,803			34	%	$	2,557			34	%
	State tax		1,583			6	%		652			6	%		474			6	%
	Australian tax		—			0	%		—			0	%		41			1	%
	Expiration of foreign tax losses		—			0	%		—			0	%		(28,202	)		-375	%
	(Increase)/ decrease in valuation allowance		(10,814	)		-40	%		(4,456	)		-40	%		25,129			334	%
		$	(1	)		0	%	$	(1	)		0	%	$	(1	)		0	%
	Deferred tax liabilities and assets are comprised of the following (in thousands):
		June 30,
		2014			2013
	Deferred tax liabilities:
	Change in accounting method adjustments	$	(804	)	$	(1,607	)
	Total deferred tax liabilities		(804	)		(1,607	)
	Deferred tax assets:
	Tax carried forward losses		2,947			2,463
	Share-based payments		2,948			1,057
	Consultant and other accruals		39			29
	Fixed and intangible assets		19,858			12,315
	Compensation accruals		319			240
	Capital loss carryforward		26,382			26,382
	Total deferred tax assets		52,493			42,486
	Valuation allowance for deferred tax assets		(51,689	)		(40,879	)
	Net deferred tax assets and liabilities	$	—		$	—
	Management evaluates the recoverability of the deferred tax assets and the amount of the required valuation allowance. Due to the uncertainty surrounding the realization of the tax deductions in future tax returns, the Company has recorded a valuation allowance against its net deferred tax assets as of June 30, 2014 and 2013. At such time as it is determined that it is more likely than not that the deferred tax assets will be realized, the valuation allowance would be reduced.
	The Company had federal and state net operating loss carryforwards of approximately $7.7 million and $5.4 million as of June 30, 2014. The federal and state net operating losses will begin to expire in 2022 and 2029, respectively. Due to the dissolution of the Company’s foreign subsidiary, all foreign tax losses expired unutilized during the year ended June 30, 2012.
	The Company’s ability to utilize its net operating loss carryforwards may be substantially limited due to ownership changes that have occurred or that could occur in the future under Section 382 of the Internal Revenue Code and similar state laws. The Company has not completed a study to determine whether one or more ownership changes have occurred.
	The Company did not previously record a deferred tax asset for any basis difference in its subsidiary because the Company intended to permanently reinvest any subsidiary earnings. However, in the year ended June 30, 2011, the Company determined that it might wind up its subsidiary. As such, the Company recorded a deferred tax asset for this difference. The Company realized this loss for tax purposes during the year ended June 30, 2012, which resulted in a capital loss carryforward of $66.2 million. This capital loss will expire in 2017.
	None of the Company’s prior income tax returns have been selected for examination by a major taxing jurisdiction; however, the statutes of limitations for various filings remain open. The oldest filings subject to potential examination for federal, state, and foreign purposes are 2011, 2010, and 2010, respectively. If the Company utilizes a net operating loss related to a closed year, the statute for that year would re-open. The Company has not reduced any tax benefit on its financial statements due to uncertain tax positions as of June 30, 2014 and it is not aware of any circumstance that would significantly change this result through the end of fiscal year 2015. To the extent the Company incurs income-tax related penalties or interest, the Company recognizes them as additional income tax expense.

Selected_Quarterly_Financial_I

Selected Quarterly Financial Information (Unaudited)	12 Months Ended
	Jun. 30, 2014
Selected Quarterly Financial Information (Unaudited)	'
	Note 11. Selected Quarterly Financial Information (Unaudited)
	The following table presents the Company’s unaudited quarterly results of operations for the years ended June 30, 2014 and 2013 (in thousands, except per share amounts).
		Quarters Ended												Year Ended
		June 30, 2014			March 31, 2014			December 31, 2013			September 30, 2013			June  30, 2014
	Net loss	$	(8,541	)	$	(7,387	)	$	(6,324	)	$	(4,896	)	$	(27,148	)
	Basic and diluted loss per share	$	(0.40	)	$	(0.34	)	$	(0.32	)	$	(0.29	)	$	(1.35	)
		Quarters Ended												Year Ended
		June 30, 2013			March 31, 2013			December 31, 2012			September 30, 2012			June  30, 2013
	Net loss	$	(3,215	)	$	(2,753	)	$	(2,754	)	$	(2,464	)	$	(11,186	)
	Basic and diluted loss per share	$	(0.19	)	$	(0.18	)	$	(0.50	)	$	(0.70	)	$	(1.10	)

The_Company_and_Summary_of_Sig1

The Company and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Reverse Stock Split and Presentation	'
	Reverse Stock Split and Presentation
	On December 18, 2012, the Company effected a 1-for-6 reverse stock split (the “2012 Reverse Stock Split”) of the Company’s common stock. As a result of the 2012 Reverse Stock Split, every six shares of the Company’s issued and outstanding common stock were combined into one share of common stock. The 2012 Reverse Stock Split did not change the number of authorized shares of the Company’s common stock, nor the common stock par value. All financial data and share information is presented on an as-adjusted basis to give effect to the 2012 Reverse Stock Split.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities.” ASU 2014-10 removes the financial reporting distinction between development stage entities and other reporting entities in United States Generally Accepted Accounting Principles. The amendment therefore eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. We early adopted ASU 2014-10 retrospectively during the year ended June 30, 2014; while the adoption of this standard impacted financial statement presentation and disclosure, it did not have a material impact on our financial condition, results of operations or cash flows.
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under accounting principles generally accepted in the Unites States of America (“U.S. GAAP”). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). Currently the Company is not generating any revenue. Therefore, the Company has not yet determined the transition method by which they will adopt the standard in 2017.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. The Company uses estimates for certain accruals including clinical and pre-clinical study fees and expenses, share-based compensation, and valuations of derivative liabilities, among others. Actual results could materially differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased.
Short-Term Investments	'
	Short-Term Investments
	Investments that have maturities of greater than three months but less than one year at the time of purchase are classified as short-term investments. Short-term investments are comprised of money market funds and U.S. government securities and are recorded at their amortized cost.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of financial instruments such as cash equivalents and other current liabilities approximate the related fair values due to the short-term maturities of these instruments. The Company invests its excess cash in financial instruments which are readily convertible into cash, consisting of money market funds and U.S. government securities. Cash is deposited in financial institutions that are FDIC insured; these deposits are in excess of the FDIC insurance limits. Financial instruments include cash and cash equivalents, short-term investments and accounts payable, which approximate fair value because of their short maturities.
	The fair value of financial assets and liabilities is measured under a three-tier fair value hierarchy as follows: Level 1 fair value is determined from observable, quoted prices in active markets for identical assets or liabilities. Level 2 fair value is determined from quoted prices for similar items in active markets or quoted prices for identical or similar items in markets that are not active. Level 3 fair value is determined using the entity’s own assumptions about the inputs that market participants would use in pricing an asset or liability. Cash equivalents, where applicable, and short-term investments are classified as Level 1 as defined by the fair value hierarchy.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash in financial institutions (which exceeds federally insured limits), and cash equivalents and short-term investments (comprised of U.S. government securities). However, management believes that the Company is not exposed to significant credit risk due to the financial positions of the depository institutions in which these deposits are held.
Intangible Assets	'
	Intangible Assets
	Intangible assets consist of patents acquired from S*Bio in August 2012, relating to a family of heterocyclic compounds that inhibit HDACs. Capitalized amounts are amortized on a straight-line basis over the expected life of the intellectual property of 14 years. The carrying values of intangible assets are periodically reviewed to determine if the facts and circumstances suggest that a potential impairment may have occurred. Results of operations for the years ended June 30, 2014 and 2013 do not reflect any write-downs associated with the potential impairment of intangible assets.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (generally three to seven years) using the straight-line method. Leasehold improvements are stated at cost and are amortized over the shorter of the estimated useful lives of the assets or the lease term.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. The Company accrues research and development costs based on work performed. In determining the amount to accrue, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.
License Fees	'
	License Fees
	Costs incurred related to the licensing of products that have not yet received regulatory approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.
Share-based Compensation	'
	Share-based Compensation
	Share-based compensation expense for employees and directors is recognized in the statement of operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, the Company estimates the grant date fair value using a binomial valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. The Company estimates the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from our estimated volatility at the grant date. For restricted stock unit (RSU) equity awards, the Company estimates the grant date fair value using the Company’s closing stock price on the date of grant. Share-based compensation recorded in the statement of operations is based on the awards expected to ultimately vest and has been reduced for estimated forfeitures. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. The Company recognizes the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which the share-based awards vest.
Interest and Dividend Income	'
	Interest and Dividend Income
	Interest on cash balances is recognized when earned. Dividend income is recognized when the right to receive the payment is established.
Income Taxes	'
	Income Taxes
	The Company’s income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of June 30, 2014 and 2013, the Company has established a valuation allowance to fully reserve its net deferred tax assets. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership of the Company may limit the amount of net operating loss carry-forwards that can be utilized in the future to offset taxable income.
	The FASB Topic on Income Taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There were no unrecognized tax benefits as of June 30, 2014 and 2013.
Derivative Liabilities	'
	Derivative Liabilities
	The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded at fair value as additional paid-in capital on our balance sheet and are not marked to market. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised, amended to remove features that result in derivative liability classification, or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of the Company’s derivative liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate. All instruments creating derivative liability accounting treatment were settled during the year ended June 30, 2012. There were no derivative liabilities as of June 30, 2014 or June 30, 2013.
Net Loss Per Share	'
	Net Loss Per Share
	Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the years ended June 30, 2014, 2013 and 2012.
	Net loss per share was determined as follows (in thousands, except share and per share amounts):
		Years ended June 30,
		2014			2013			2012
	Numerator
	Net loss	$	(27,148	)	$	(11,186	)	$	(7,523	)
	Denominator
	Weighted average common shares outstanding		20,061,387			10,160,835			2,247,709
	Basic and diluted net loss per share	$	(1.35	)	$	(1.10	)	$	(3.35	)
	Because the Company is in a net loss position, it has excluded stock options, warrants, unvested restricted stock units and convertible preferred stock from its calculation of diluted net loss per share, and the Company’s diluted net loss per share is the same as the Company’s basic net loss per share. For the years ended June 30, 2014, 2013 and 2012, the Company did not have any items that would be classified as other comprehensive income or losses. The table below presents the potentially dilutive securities that would have been included in the Company’s calculation of diluted net loss per share allocable to common stockholders as if they were not antidilutive as of June 30, 2014, 2013 and 2012.
		Year ended June 30,
		2014			2013			2012
	Anti-dilutive securities not included in diluted loss per share:
	Stock options		1,194,854			635,094			143,927
	Warrants		4,900,999			5,062,000			937,295
	Restricted stock units		400,000			400,000			—
	Convertible preferred shares		—			—			804,500
	Total anti-dilutive securities not included in diluted net loss per share		6,495,853			6,097,094			1,885,722

The_Company_and_Summary_of_Sig2

The Company and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Net Loss Per Share	'
	Net loss per share was determined as follows (in thousands, except share and per share amounts):
		Years ended June 30,
		2014			2013			2012
	Numerator
	Net loss	$	(27,148	)	$	(11,186	)	$	(7,523	)
	Denominator
	Weighted average common shares outstanding		20,061,387			10,160,835			2,247,709
	Basic and diluted net loss per share	$	(1.35	)	$	(1.10	)	$	(3.35	)
Antidilutive Securities	'
	The table below presents the potentially dilutive securities that would have been included in the Company’s calculation of diluted net loss per share allocable to common stockholders as if they were not antidilutive as of June 30, 2014, 2013 and 2012.
		Year ended June 30,
		2014			2013			2012
	Anti-dilutive securities not included in diluted loss per share:
	Stock options		1,194,854			635,094			143,927
	Warrants		4,900,999			5,062,000			937,295
	Restricted stock units		400,000			400,000			—
	Convertible preferred shares		—			—			804,500
	Total anti-dilutive securities not included in diluted net loss per share		6,495,853			6,097,094			1,885,722

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Intangible Assets	'
	Intangible assets consisted of the following, in thousands:
		June 30,
		2014			2013
	S*Bio Patents – Gross	$	500		$	500
	S*Bio Patents – Accumulated amortization		(65	)		(30	)
	Intangible assets, net	$	435		$	470

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Property and Equipment	'
	Property and equipment consisted of the following, in thousands:
		June 30,
		2014			2013
	Furniture and equipment	$	107		$	67
	Leasehold improvements		32			22
			139			89
	Less: accumulated depreciation		(56	)		(41	)
	Property and equipment, net	$	83		$	48

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Jun. 30, 2014
Accrued Liabilities	'
	Accrued liabilities consisted of the following, in thousands:
		June 30,
		2014		2013
	Accrued pre-clinical and clinical trial expenses	$	1,899	$	279
	Accrued compensation and benefits		800		604
	Accrued legal and professional services expenses		102		145
	Other		107		110
	Total accrued liabilities	$	2,908	$	1,138

Sharebased_Compensation_Tables

Share-based Compensation (Tables)	12 Months Ended
	Jun. 30, 2014
Share-Based Compensation Expense for Stock Awards	'
	Total share-based compensation expense for all stock awards consists of the following, in thousands:
		Years Ended June 30,
		2014			2013			2012
	Research and development	$	1,549		$	213		$	65
	General and administrative		3,198			1,293			446
	Total share-based compensation	$	4,747		$	1,506		$	511
Summary of Stock Option Activity and Related Data	'
	A summary of the Company’s stock option activity and related data follows:
		Number of			Weighted-Average			Weighted-Average			Aggregate
		Options			Exercise Price			Remaining Contractual			Intrinsic Value
								Term (in years)
	Outstanding at June 30, 2013		635,094		$	8.26
	Granted		568,593			7.97
	Expired		(8,833	)		10.33
	Outstanding at June 30, 2014		1,194,854		$	8.11			3.7		$	340,397
	Vested and exercisable at June 30, 2014		326,363		$	8.94			2.7		$	173,574
Fair Value of Stock Options Weighted-Average Assumptions Used	'
	The Company uses a binomial valuation model to estimate the grant date fair value of stock options. To calculate these fair values, the following weighted-average assumptions were used:
		Years ended June 30,
		2014			2013			2012
	Risk-free interest rate		1.5	%		0.7	%		1.2	%
	Expected life (years)		5			5			5
	Expected volatility		145.9	%		159.3	%		146.5	%
	Dividend yield		0	%		0	%		0	%
	Grant date fair value	$	6.85		$	6.57		$	8.56

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Pre-Tax Loss Information	'
	Pre-tax loss consists of the following jurisdictions (in thousands):
		Years ended June 30,
		2014			2013			2012
	Domestic	$	(27,147	)	$	(11,185	)	$	(8,546	)
	Foreign		—			—			1,024
	Pre-tax loss	$	(27,147	)	$	(11,185	)	$	(7,522	)
Recociliation of Income Taxes Computed at U.S Federal Statutory Tax Rates to Income Tax Expense	'
	The reconciliation of income tax computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):
		Years Ended June 30,
		2014						2013						2012
		$			%			$			%			$			%
	Tax benefit at U.S. statutory rates	$	9,230			34	%	$	3,803			34	%	$	2,557			34	%
	State tax		1,583			6	%		652			6	%		474			6	%
	Australian tax		—			0	%		—			0	%		41			1	%
	Expiration of foreign tax losses		—			0	%		—			0	%		(28,202	)		-375	%
	(Increase)/ decrease in valuation allowance		(10,814	)		-40	%		(4,456	)		-40	%		25,129			334	%
		$	(1	)		0	%	$	(1	)		0	%	$	(1	)		0	%
Deferred Tax Liabilities and Assets	'
	Deferred tax liabilities and assets are comprised of the following (in thousands):
		June 30,
		2014			2013
	Deferred tax liabilities:
	Change in accounting method adjustments	$	(804	)	$	(1,607	)
	Total deferred tax liabilities		(804	)		(1,607	)
	Deferred tax assets:
	Tax carried forward losses		2,947			2,463
	Share-based payments		2,948			1,057
	Consultant and other accruals		39			29
	Fixed and intangible assets		19,858			12,315
	Compensation accruals		319			240
	Capital loss carryforward		26,382			26,382
	Total deferred tax assets		52,493			42,486
	Valuation allowance for deferred tax assets		(51,689	)		(40,879	)
	Net deferred tax assets and liabilities	$	—		$	—

Selected_Quarterly_Financial_I1

Selected Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2014
Unaudited Quarterly Results of Operations	'
	The following table presents the Company’s unaudited quarterly results of operations for the years ended June 30, 2014 and 2013 (in thousands, except per share amounts).
		Quarters Ended												Year Ended
		June 30, 2014			March 31, 2014			December 31, 2013			September 30, 2013			June  30, 2014
	Net loss	$	(8,541	)	$	(7,387	)	$	(6,324	)	$	(4,896	)	$	(27,148	)
	Basic and diluted loss per share	$	(0.40	)	$	(0.34	)	$	(0.32	)	$	(0.29	)	$	(1.35	)
		Quarters Ended												Year Ended
		June 30, 2013			March 31, 2013			December 31, 2012			September 30, 2012			June  30, 2013
	Net loss	$	(3,215	)	$	(2,753	)	$	(2,754	)	$	(2,464	)	$	(11,186	)
	Basic and diluted loss per share	$	(0.19	)	$	(0.18	)	$	(0.50	)	$	(0.70	)	$	(1.10	)

Company_and_Summary_of_Signifi

Company and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Dec. 18, 2012	Dec. 31, 2000	Jun. 30, 2014	Jun. 30, 2013
Targeted or Tracking Stock, Stock [Line Items]	'	'	'	'
Incorporation date, year and month	'	'2000-12	'	'
Reverse stock split ratio	0.1667	'	'	'
Reverse stock split description	'	'	'On December 18, 2012, the Company effected a 1-for-6 reverse stock split (the "2012 Reverse Stock Split") of the Company's common stock.	'
Highly liquid investments, maturity period maximum	'	'	'3 months	'
Estimated life of the intellectual property	'	'	'14 years	'
Impairment of intangible assets	'	'	$0	$0
Percentage of likelihood of income tax being sustained	'	'	50.00%	'
Unrecognized tax benefits	'	'	$0	$0
Minimum	'	'	'	'
Targeted or Tracking Stock, Stock [Line Items]	'	'	'	'
Property and equipment, estimated useful life	'	'	'3 years	'
Maximum	'	'	'	'
Targeted or Tracking Stock, Stock [Line Items]	'	'	'	'
Property and equipment, estimated useful life	'	'	'7 years	'

Components_of_Net_Loss_Per_Sha

Components of Net Loss Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Numerator	'	'	'	'	'	'	'	'	'	'	'
Net loss	($8,541)	($7,387)	($6,324)	($4,896)	($3,215)	($2,753)	($2,754)	($2,464)	($27,148)	($11,186)	($7,523)
Denominator	'	'	'	'	'	'	'	'	'	'	'
Weighted average common shares outstanding	'	'	'	'	'	'	'	'	20,061,387	10,160,835	2,247,709
Basic and diluted net loss per share	($0.40)	($0.34)	($0.32)	($0.29)	($0.19)	($0.18)	($0.50)	($0.70)	($1.35)	($1.10)	($3.35)

Antidilutive_Securities_Detail

Antidilutive Securities (Detail)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Anti-dilutive securities not included in diluted loss per share:	'	'	'
Total anti-dilutive securities not included in diluted net loss per share	6,495,853	6,097,094	1,885,722
Stock Option	'	'	'
Anti-dilutive securities not included in diluted loss per share:	'	'	'
Total anti-dilutive securities not included in diluted net loss per share	1,194,854	635,094	143,927
Warrants	'	'	'
Anti-dilutive securities not included in diluted loss per share:	'	'	'
Total anti-dilutive securities not included in diluted net loss per share	4,900,999	5,062,000	937,295
Restricted Stock Unit	'	'	'
Anti-dilutive securities not included in diluted loss per share:	'	'	'
Total anti-dilutive securities not included in diluted net loss per share	400,000	400,000	'
Convertible Preferred Stock	'	'	'
Anti-dilutive securities not included in diluted loss per share:	'	'	'
Total anti-dilutive securities not included in diluted net loss per share	'	'	804,500

Schedule_of_Intangible_Assets_

Schedule of Intangible Assets (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, net	$435	$470
S*Bio Patents	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets - Gross	500	500
Intangible assets - Accumulated amortization	-65	-30
Intangible assets, net	$435	$470

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Finite-Lived Intangible Assets [Line Items]	'	'	'
Amortization expense	$35,000	$30,000	$0
S*Bio Patents	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Expected amortization expense per year	$35,000	'	'
Amortization period	'2026	'	'

Schedule_of_Property_and_Equip

Schedule of Property and Equipment (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, Gross	$139	$89
Less: accumulated depreciation	-56	-41
Property and equipment, net	83	48
Furniture and Equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, Gross	107	67
Leasehold Improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, Gross	$32	$22

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation expense	$15,000	$15,000	$13,000

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Line Items]	'	'
Accrued pre-clinical and clinical trial expenses	$1,899	$279
Accrued compensation and benefits	800	604
Accrued legal and professional services expenses	102	145
Other	107	110
Total accrued liabilities	$2,908	$1,138

Related_Party_Transaction_Addi

Related Party Transaction - Additional Information (Detail) (USD $)	2 Months Ended	12 Months Ended			1 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 31, 2011	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	31-May-12	11-May-12	Mar. 31, 2012	Jun. 30, 2014	Dec. 31, 2012
					Securities Subscription Agreement With Novogen	Securities Subscription Agreement With Novogen	Rights Offering	Rights Offering	Rights Offering	Rights Offering	Novogen
											Warrants Cancelled
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of shares of common stock in each unit	'	'	'	'	'	'	'	0.0833	0.0833	'	'
Number of warrants in each unit	'	'	'	'	'	'	'	'	1	'	'
Number of shares each warrant to purchase of common stock	'	'	'	'	'	'	'	0.04167	0.04167	'	'
Number of subscription right unit issued	'	'	'	'	'	'	8,988,675	11,660,606	'	'	'
stock issued	215,667	'	'	'	'	'	749,056	971,700	'	'	'
Warrants issued	'	'	'	'	'	'	374,528	485,857	'	'	'
Warrant exercisable period	'	'	'	'	'	'	'5 years	'5 years	'	'	'
Exercise price per share	'	'	'	'	'	'	7.14	7.14	'	7.14	'
Warrants to purchase common stock	'	'	'	'	'	'	'	'	'	'	166,666
Issuance of Common Stock	'	21,607,296	17,116,571	'	323,625	222,222	'	'	'	'	'
Purchase Price of common stock issued	'	'	'	'	$6.18	$9	'	'	'	'	'
Proceeds from Issuance of Common Stock	'	$32,721	$39,453	$9,831	$2,000	$2,000	'	$4,800	'	'	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

2 Months Ended

12 Months Ended

15 Months Ended

19 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

Aug. 22, 2012

Sep. 28, 2011

31-May-11

Aug. 31, 2011

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2014

Jun. 30, 2014

Apr. 30, 2014

Aug. 07, 2012

Sep. 30, 2011

Dec. 31, 2012

31-May-11

Jun. 30, 2014

Jun. 30, 2012

Sep. 30, 2011

Jun. 30, 2012

Sep. 28, 2011

31-May-12

11-May-12

Mar. 31, 2012

Jun. 30, 2014

11-May-12

Dec. 31, 2012

Dec. 29, 2011

31-May-11

31-May-11

11-May-11

31-May-11

31-May-11

Dec. 31, 2011

Sep. 30, 2011

Dec. 29, 2011

Apr. 30, 2014

Apr. 30, 2011

Mar. 30, 2012

31-May-11

11-May-11

31-May-11

31-May-11

Oct. 31, 2013

Apr. 30, 2013

Dec. 31, 2012

Jun. 30, 2014

Phase Three Clinical Trial

Series A warrants

Series A warrants

Series A warrants

Series A warrants

Series A warrants

Series B warrants

Series B warrants

Series B warrants

Rights Offering

Rights Offering

Rights Offering

Rights Offering

Subscription Rights

Warrants Cancelled

Amended Purchase Agreement

Amended Purchase Agreement

Amended Purchase Agreement

Amended Purchase Agreement

Amended Purchase Agreement

Amended Purchase Agreement

Securities Subscription Agreement With Novogen

Securities Subscription Agreement With Novogen

Securities Subscription Agreement With Novogen

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

Minimum

Underwritten Registered Offering

Underwritten Registered Offering

December 2012 Private Placement

December 2012 Private Placement

Rights Offering

Novogen

Series A warrants

Series B warrants

Series B warrants

Placement Agent

Amended Purchase Agreement

Rights Offering

Amended Purchase Agreement

Amended Purchase Agreement

Amended Purchase Agreement

Amended Purchase Agreement

Series A warrants

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

stock issued

'

'

'

215,667

'

'

'

'

'

'

'

'

'

194,381

'

'

'

50,934

'

'

749,056

971,700

'

'

'

'

111,212

139,203

'

'

'

'

'

'

40,950

'

'

'

'

'

'

'

4,375,000

2,030,000

9,166,665

'

Purchase price common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8

$7.50

'

'

Proceeds from Issuance of Common Stock

'

'

'

'

$32,721,000

$39,453,000

$9,831,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,800,000

'

'

'

'

'

'

'

'

'

'

$2,000,000

$2,000,000

'

'

'

'

'

'

'

'

$32,700,000

$14,200,000

$27,500,000

'

Warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

374,528

485,857

'

'

'

'

'

'

'

'

'

35,008

'

'

'

'

'

'

'

'

'

'

'

'

6,416,665

'

Proceed from issuance of private placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,300,000

'

Warrants exercised

'

'

'

'

'

'

'

'

'

2,046,871

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon exercise of warrants

'

'

'

'

'

'

'

'

'

1,496,018

'

'

'

119,158

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock to acquire intellectual property and technology rights

195,756

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock value

'

'

'

'

0

0

'

'

0

0

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

166,666

'

'

'

'

'

'

'

'

'

'

'

17,129,361

'

'

'

'

'

'

'

'

Aggregate purchase price of subscription rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,600,000

'

'

'

'

'

'

'

'

Number of warrants in each unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.0833

0.0833

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.04167

0.04167

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

'

'

7.14

7.14

'

7.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.12

Purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.445

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.34

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of subscription right unit issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,988,675

11,660,606

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment warrants, exercisable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

'

'

3,707

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of Common Stock

'

'

'

'

21,607,296

17,116,571

'

'

21,607,296

21,607,296

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

323,625

222,222

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Price of common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.18

$9

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercisable

'

'

'

161,750

'

'

'

'

'

'

'

'

108,942

'

'

'

'

145,256

'

'

'

'

'

'

'

'

'

'

104,402

'

360,922

'

'

'

'

'

'

'

'

'

375,094

'

'

'

'

'

Price of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8

$8

'

$4.50

'

'

'

'

Limit of issuable shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

388,764

'

'

108,207

'

'

'

'

Investment warrants exercise price

'

'

'

'

'

'

'

'

'

'

'

'

$6

'

$9.42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount equivalent of the number of shares of common stock issued on exercise of series B warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration period of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The initial exercise price per share of the Series B warrants was equal to the lower of (i) $8.00, and (ii) 85% of the arithmetic average of the lowest eight weighted average prices of the common stock during the 20 consecutive trading day period in the case of a voluntary exercise by the holders, ending on the trading day immediately preceding the date of delivery of a notice of exercise.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of warrants

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

215,721

'

'

'

0

'

'

'

315,484

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,369,794

Cash payments to investors in aggregate amount

'

365,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment for financing Costs

'

41,000

'

'

'

'

406,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative liabilities

'

'

1,200,000

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Excess of fair value of derivative liabilities over proceeds of private placement

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liabilities in excess of the proceeds

'

'

508,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on adjustment to fair value of derivative liabilities

'

'

'

'

'

'

1,139,000

49,000

'

'

'

'

'

'

'

'

14,000

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of shares and warrants under agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000,000

50,000,000

'

'

'

'

'

'

'

'

'

Public float maximum market value

'

'

'

'

'

'

'

'

'

'

$75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total authorized share capital

'

'

'

'

113,100,000

'

'

'

113,100,000

113,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

'

'

'

113,000,000

113,000,000

'

'

113,000,000

113,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

'

'

'

'

$0.00

$0.00

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

'

'

'

'

100,000

100,000

'

'

100,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value per share

'

'

'

'

$0.01

$0.01

'

'

$0.01

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares outstanding

'

'

'

'

0

0

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2016-11

'

'

'

'

'

'

'

'2017-05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2017-12

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

In Millions, except Share data, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 29, 2013

Jun. 30, 2014

Mar. 29, 2013

Mar. 29, 2013

Mar. 29, 2013

Mar. 29, 2013

Mar. 29, 2013

Mar. 29, 2013

2008 Omnibus Plan

Stock Compensation Plan

Stock Compensation Plan

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Vesting Schedule One

Vesting Schedule Two

Vesting Schedule Three

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock authorized

'

'

'

2,186,000

'

'

'

'

'

'

'

'

'

'

Shares available for future grant

'

'

'

657,479

'

'

'

'

'

'

'

'

'

'

Options outstanding

1,194,854

635,094

'

'

1,194,854

66,333

'

'

'

'

'

'

'

'

Closing price of common stock

'

'

'

'

$6.34

'

'

'

'

'

'

'

'

'

Stock option exercised

0

0

0

'

'

'

'

'

'

'

'

'

'

'

Total fair value of options vested

$1.20

$0.90

$0.30

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation expense related to non-vested stock options

3.3

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected weighted average period for recognition of compensation expense

'3 years 1 month 6 days

'

'

'

'

'

'

'2 years 2 months 12 days

'

'

'

'

'

'

RSUs granted

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

One third of RSUs vesting date

'

'

'

'

'

'

'

'

'

'

'

30-Aug-14

30-Aug-15

30-Aug-16

Number of common stock to be received for each RSUs

'

'

'

'

'

'

'

'

'

'

1

'

'

'

Fair value of RSUs on the date of grant

'

'

'

'

'

'

'

'

3.5

'

'

'

'

'

RSUs grant date fair value per unit

'

'

'

'

'

'

$8.63

'

'

'

'

'

'

'

Unrecognized compensation expense related to non-vested RSUs

'

'

'

'

'

'

'

$1.40

'

'

'

'

'

'

ShareBased_Compensation_Expens

Share-Based Compensation Expense for Stock Awards (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share based compensation	$4,747	$1,506	$511
Research and development	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share based compensation	1,549	213	65
General and administrative	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share based compensation	$3,198	$1,293	$446

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity and Related Data (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014
Number of Options	'
Beginning Balance	635,094
Granted	568,593
Expired	-8,833
Ending balance	1,194,854
Vested and exercisable at end of period	326,363
Weighted- Average Exercise Price	'
Beginning Balance	$8.26
Granted	$7.97
Expired	$10.33
Ending balance	$8.11
Vested and exercisable at end of period	$8.94
Weighted Average Remaining Contractual Term (in years)	'
Outstanding at end of period	'3 years 8 months 12 days
Vested and exercisable at end of period	'2 years 8 months 12 days
Aggregate Intrinsic Value	'
Outstanding at end of period	$340,397
Vested and exercisable at end of period	$173,574

Fair_Value_of_Stock_Options_We

Fair Value of Stock Options Weighted-Average Assumptions Used (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share based Compensation Arrangement Assumptions Used to Estimate Fair Values of Share Options Granted [Line Items]	'	'	'
Risk-free interest rate	1.50%	0.70%	1.20%
Expected life (years)	'5 years	'5 years	'5 years
Expected volatility	145.90%	159.30%	146.50%
Dividend yield	0.00%	0.00%	0.00%
Grant date fair value	$6.85	$6.57	$8.56

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended			12 Months Ended
	Sep. 28, 2012	Aug. 22, 2012	Aug. 07, 2012	Jun. 30, 2014	Jun. 30, 2013	Aug. 07, 2012
				sqft
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'	'	'	'	'	'
Lease expiration month and year	'	'	'	'2015-06	'	'
Lease arrangement rent area, square feet	'	'	'	8,800	'	'
Future minimum payment next year	'	'	'	$303,000	'	'
Issuance of common stock to acquire intellectual property and technology rights	'	'	500,000	'	'	'
Issuance of common stock to purchase asset, shares	'	195,756	'	'	'	'
Future aggregate milestone payments	'	'	'	'	'	75,200,000
First milestone payment	'	'	200,000	'	'	'
Common stock value	'	'	'	0	0	'
Percentage of Purchase Requirement	100.00%	'	'	'	'	'
License and supply agreement notice period	'90 days	'	'	'	'	'
Phase Three Clinical Trial	'	'	'	'	'	'
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'	'	'	'	'	'
Common stock value	'	'	500,000	'	'	500,000
Minimum	'	'	'	'	'	'
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'	'	'	'	'	'
Lease rental rate	'	'	'	25,077	'	'
Maximum	'	'	'	'	'	'
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'	'	'	'	'	'
Lease rental rate	'	'	'	$25,957	'	'

Segment_Information_Additional

Segment Information - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2014
	Segment
Segment Reporting Information [Line Items]	'
Number of operating segments	1
Number of geographic segments	2

PreTax_Loss_Jurisdictions_Deta

Pre-Tax Loss Jurisdictions (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Reconciliation of Statutory Federal Tax Rate [Line Items]	'	'	'
Domestic	($27,147)	($11,185)	($8,546)
Foreign	'	'	1,024
Pre-tax loss	($27,147)	($11,185)	($7,522)

Reconciliation_of_Income_Taxes

Reconciliation of Income Taxes Computed at U.S Federal Statutory Tax rates to Income Tax Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Reconciliation of Statutory Federal Tax Rate [Line Items]	'	'	'
Tax benefit at U.S. statutory rates	$9,230	$3,803	$2,557
State tax	1,583	652	474
Australian tax	'	'	41
Expiration of foreign tax losses	'	'	-28,202
(Increase)/decrease in valuation allowance	-10,814	-4,456	25,129
Income tax expense	($1)	($1)	($1)
Tax benefit at U.S. statutory rates	34.00%	34.00%	34.00%
State tax	6.00%	6.00%	6.00%
Australian tax	0.00%	0.00%	1.00%
Expiration of foreign tax losses	0.00%	0.00%	-375.00%
(Increase)/ decrease in valuation allowance	-40.00%	-40.00%	334.00%
Effective Income Tax Rate, Continuing Operations, Total	0.00%	0.00%	0.00%

Deferred_Tax_Liabilities_and_A

Deferred Tax Liabilities and Assets (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Deferred tax liabilities:	'	'
Change in accounting method adjustments	($804)	($1,607)
Total deferred tax liabilities	-804	-1,607
Deferred tax assets:	'	'
Tax carried forward losses	2,947	2,463
Share-based payments	2,948	1,057
Consultant and other accruals	39	29
Fixed and intangible assets	19,858	12,315
Compensation accruals	319	240
Capital loss carryforward	26,382	26,382
Total deferred tax assets	52,493	42,486
Valuation allowance for deferred tax assets	-51,689	-40,879
Net deferred tax assets and liabilities	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2012	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
			Federal	State
Income Taxes [Line Items]	'	'	'	'
Federal net operating loss carry forwards	'	$7.70	'	'
State net operating loss carry forwards	'	5.4	'	'
Expiration year of operating loss carry forwards	'	'	'2022	'2029
Capital Loss Carry Forward	$66.20	'	'	'
Capital Loss Expiration Year	'2017	'	'	'

Quarterly_Financial_Informatio

Quarterly Financial Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Quarterly Financial Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net loss	($8,541)	($7,387)	($6,324)	($4,896)	($3,215)	($2,753)	($2,754)	($2,464)	($27,148)	($11,186)	($7,523)
Basic and diluted loss per share	($0.40)	($0.34)	($0.32)	($0.29)	($0.19)	($0.18)	($0.50)	($0.70)	($1.35)	($1.10)	($3.35)